Standout Papers

Nivolumab in patients with metastatic DNA mismatch ... 2009 2026 2014 2020 1.9k
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (2017)
    Michael J. Overman, Ray McDermott et al. The Lancet Oncology
  2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer (2018)
    Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology
  3. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy (2009)
    Scott Kopetz, George J. Chang et al. Journal of Clinical Oncology
  4. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (2017)
    Rodrigo Dienstmann, Louis Vermeulen et al. Nature reviews. Cancer
  5. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer (2011)
    Ben Tran, Scott Kopetz et al. Cancer
  6. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer (2015)
    Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology
  7. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA (2015)
    Richard B. Lanman, Stefanie Mortimer et al. PLoS ONE
  8. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 (2019)
    Jonathan M. Loree, Seerat Anand et al. JAMA Oncology
  9. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study (2021)
    Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology
  10. Biomarker-guided therapy for colorectal cancer: strength in complexity (2019)
    Anita Sveen, Scott Kopetz et al. Nature Reviews Clinical Oncology
  11. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 (2022)
    Thierry André, Sara Lonardi et al. Annals of Oncology
  12. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024)
    Yasutoshi Kuboki, Marwan Fakih et al. Nature Medicine
  13. Advancements in combining targeted therapy and immunotherapy for colorectal cancer (2024)
    Manisha Singh, Van K. Morris et al. Trends in cancer
  14. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial (2025)
    Scott Kopetz, Takayuki Yoshino et al. Nature Medicine

Immediate Impact

4 by Nobel laureates 10 from Science/Nature 83 standout
Sub-graph 1 of 21

Citing Papers

SOX17 enables immune evasion of early colorectal adenomas and cancers
2024 StandoutNature
Targeting KRAS in cancer
2024 Standout
21 intermediate papers

Works of Scott Kopetz being referenced

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
2022
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
2015 Standout
and 29 more

Author Peers

Author Last Decade Papers Cites
Scott Kopetz 19936 7393 7399 661 28.1k
Heinz‐Josef Lenz 23991 7979 6275 856 34.9k
Salvatore Siena 26080 8267 6860 531 36.7k
Steven Gallinger 16517 8453 6876 346 25.0k
Herbert I. Hurwitz 17516 2918 4743 318 26.3k
Armando Santoro 17399 8609 3757 903 33.7k
Filippo de Braud 17473 3280 3589 749 26.0k
Fortunato Ciardiello 21501 4479 5351 626 33.5k
Andrés Cervantes 17546 3784 3199 459 26.9k
Leonard B. Saltz 27418 5864 4143 533 37.4k
John D. Hainsworth 21144 6869 5167 623 36.4k

All Works

Loading papers...

Rankless by CCL
2026